John is currently the Head of Region US, Global Rare Diseases at Chiesi Group.
John oversees the US and South American rare disease commercial efforts including strategic marketing, sales, market access, government pricing and reimbursement.
Prior to this John was the Director of Sales for Apobiologix, where he led the commercial planning and go-to-market strategy for the newly formed biosimilar franchise in the US.
John has 25 years of industry experience and has held numerous senior commercial roles in oncology and cardiovascular franchises within start-up to large multinational organizations.
Before joining Chiesi Canada, John was with Daiichi Sankyo for 19 years serving as the National Director of Oncology Sales where he launched Zelboraf® (vemurafenib).
In this role, he also served as a member of the pexidartinib and tivantinib global new product teams.
Before this, John was the West Area Business Director in Phoenix, Arizona. He was selected as a “charter member” in 1996 to launch Camptosar® (irinotecan) and led commercial teams through multiple mergers and acquisitions. John began his career at Roberts Pharmaceuticals in Seattle, Washington.
John holds a BA in Political Science from Ohio Wesleyan University. He enjoys skiing, sailing, and traveling with his wife and two daughters.